The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Effect of Age and Lenvatinib on OS in Thyroid Cancer

Marcia S. Brose, MD, PhD
Published Online: 6:39 PM, Sun May 31, 2015


Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in the SELECT trial.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.